The new treatment, Tenecteplase, is said to have similar outcomes in limiting the damage done in the brain after a stroke compared with current treatments, it is also far easier to administer and may also be safer, they said.
The results for the new drug treatment were published today in the journal 'Lancet Neurology'.
Crucially however, it is also far easier to administer and may also be safer.
Ischaemic strokes are caused by a blood clot blocking a blood vessel in the brain, and are treated by injecting 'clot-busting' drugs that dissolve the blood clot, restoring blood flow.
Currently, only one drug - Alteplase - is used for acute treatment of stroke.
The study, led by Professor Keith Muir, SINAPSE Chair of Clinical Imaging and Consultant Neurologist at the University of Glasgow, compared Alteplase with a newer clot-busting drug called Tenecteplase.
The study, funded by the Stroke Association, showed that incidences of serious adverse events did not differ between the two groups and all neurological and radiological outcomes were similar, despite there being slightly more very severe strokes in the Tenecteplase group.
Researchers believe that, as Tenecteplase can be given more easily than Alteplase, it could become a less expensive and easier to administer treatment for ischaemic stroke patients.
However, a larger clinical trial will be needed in the lab to test Tenecteplase fully, and plans for such a trial are at an advanced stage.
Professor Muir said: "Every minute is crucial in treating stroke and we need better treatment options. Any treatment that is easier to deliver and potentially safer could mean the difference between a good recovery and someone suffering serious debilitating long term effects.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
